Drugs / motesanib
Trials 19 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT01386866 | May 2009 → Nov 2010 | cancer | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00448786 | Feb 2007 → Dec 2008 | cancer | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00322400 | Mar 2006 → Apr 2009 | female breast carcinoma | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00861419 | Dec 2005 → ? | cancer | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00324597 | Oct 2005 → ? | lung cancer, lymphoma, lymphoproliferative syndrome | Jonsson Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 1 | NCT00101907 | Dec 2004 → Jun 2007 | esophageal cancer, lung cancer, malignant pancreatic neoplasm | Amgen | Terminated | No outcome recorded |
| Phase 1 | NCT00101894 | Dec 2004 → Apr 2010 | colon carcinoma, rectal carcinoma | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00093873 | Jul 2003 → Feb 2006 | neoplasm | Amgen | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01349088 | Dec 2013 → Sep 2015 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00094835 | Jan 2005 → Mar 2007 | non-small cell lung carcinoma | Amgen | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT00427349 | Nov 2008 → Oct 2014 | carcinoid tumor, digestive system neuroendocrine neoplasm, neoplastic syndrome | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00574951 | Dec 2007 → Jul 2013 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Gynecologic Oncology Group | Terminated | No outcome recorded |
| Phase 2 | NCT00369070 | Jan 2007 → Apr 2008 | non-small cell lung carcinoma | Amgen | Terminated | No outcome recorded |
| Phase 2 | NCT00356681 | Dec 2006 → Feb 2009 | female breast carcinoma | Amgen | Terminated | No outcome recorded |
| Phase 2 | NCT00360867 | Dec 2005 → Jul 2012 | cancer | Amgen | Terminated | No outcome recorded |
| Phase 2 | NCT00254267 | Nov 2005 → Feb 2007 | gastrointestinal stromal tumor | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00121628 | Jul 2005 → Nov 2006 | thyroid cancer | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00089960 | Oct 2004 → Jun 2006 | gastrointestinal stromal tumor | Amgen | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02629848 | Jul 2012 → Sep 2014 | non-small cell lung carcinoma | Takeda | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01235416 Comparator | Sep 2005 → Apr 2008 | — | Amgen | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00460317 Comparator | Jul 2007 → Mar 2011 | non-small cell lung carcinoma | Amgen | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-02-17 | Takeda | Takeda Announces Phase 3 MONET-A Study Evaluating Motesanib (AMG 706) in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint takeda.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | motesanib | “Gallbladder toxicity, including cholecystitis, has been reported with motesanib, an orally administered small-molecule antagonist of VEGFRs 1, 2 and 3; PDGFR; and Kit.” PMID 23679351 ↗ May 20139“Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.” PMID 20838998 ↗ Sep 2010 “This study explored the activity of another oral VEGF inhibitor, AMG 706 or motesanib, a multikinase inhibitor that targets receptor tyrosine kinases” PMID 29853660 ↗ May 2018 “Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients” PMID 24419239 ↗ Jan 2014 “Single oral dose of 125 mg AMG 706 (motesanib)” NCT01386866 ↗ |
| Known as | AMG 706 | “Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.” PMID 17557949 ↗ Jun 2007 |
| Known as | motesanib diphosphate | “Motesanib diphosphate (AMG 706) is a novel oral inhibitor of VEGF receptors, platelet-derived growth-factor receptor, and KIT.” PMID 18596272 ↗ Jul 20082“treatment with AMG 706 (motesanib diphosphate) in combination with paclitaxel and carboplatin” NCT00460317 ↗ “Drug: motesanib diphosphate” NCT00574951 ↗ |
| Known as | Motesanib phosphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL572881 ↗ |
| Action | Inhibit | “motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors” PMID 20838998 ↗ Sep 20101“Tyrosine-protein kinase receptor RET inhibitor” CHEMBL572881 ↗ |
| Modality | Small molecule | “AMG 706 is a small organic molecule” NCT00101894 ↗ |
| Route | Oral | “Patients with advanced GIST who failed imatinib mesylate after ≥8 weeks of treatment with ≥600 mg daily received motesanib 125 mg orally once daily continuously for 48 weeks” PMID 20838998 ↗ Sep 2010 |
| Target | KIT | “motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors” PMID 20838998 ↗ Sep 2010 |
| Target | RET | “Tyrosine-protein kinase receptor RET inhibitor” CHEMBL572881 ↗ |